A lactylation-related gene signature predicts prognosis and immunotherapy response in clear cell renal cell carcinoma based on machine learning and multi-omics analysis
Open Access
- 12 March 2026
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Abstract
Clear cell renal cell carcinoma (ccRCC) is a highly heterogeneous malignancy with complex molecular features, posing significant challenges for accurate prognosis prediction and treatment stratification. Lactylation, an emerging epigenetic regulatory mechanism, plays a pivotal role in tumor progression and immune microenvironment remodeling. This study aims to develop a lactylation-related gene signature (LRGS) and systematically evaluate its prognostic value and potential for guiding clinical interventions in ccRCC. We developed a machine learning-derived lactylation signature using lactylation-related genes (LRGs) selected through bulk and single-cell RNA sequencing data. The model’s performance was subsequently validated using internal (TCGA-KIRC) and external (E-MTAB-1980) cohorts. The associations of LRGS with clinical characteristics, immune cell infiltration, and drug response were further analyzed. The functions of the key risk gene SHC1 were investigated using in vitro experiments. Ultimately, an 11-gene LRGS was identified that effectively predicts the prognosis of ccRCC patients. This model demonstrated robust predictive capability in an external dataset (AUC > 0.7). Univariate and multivariate analyses indicated that the model’s risk score was an independent predictor of clinical outcomes. The high-risk group exhibited significant infiltration of Tregs and a higher tumor immune dysfunction score, indicating a poorer responsiveness to immunotherapy. Finally, cell experiments confirmed that inhibiting SHC1 expression suppressed the proliferation and migration of ccRCC cells. In conclusion, we successfully constructed a novel LRGS, which provides a new perspective for risk stratification and personalized treatment of ccRCC.Keywords
Funding Information
- Shanghai Putuo District Health System Science and Technology Innovation Project (ptkwws202419)
- National Natural Science Foundation of China (82305141)
This publication has 49 references indexed in Scilit:
- MUC1/CA15-3 identifies a clear cell renal carcinoma characterized by Sunitinib response with a specific metabolic signatureClinical and Experimental Medicine, 2026
- The Clinical Prognostic Value of Lactylation-Regulated Proteins in Gastric CancerJournal of Proteome Research, 2025
- Development of a lactylation-related molecular classification and machine learning-based gene signature to predict survival, response to immunotherapy for ovarian cancerPathology - Research and Practice, 2025
- Transcriptomic and proteo-metabolic determinants of the grading system in clear cell renal cell carcinomaUrologic Oncology: Seminars and Original Investigations, 2025
- Epidemiology of Renal Cell Carcinoma: 2022 UpdateEuropean Urology, 2022
- Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatmentUrologic Oncology: Seminars and Original Investigations, 2019
- Heterogeneity in renal cell carcinomaUrologic Oncology: Seminars and Original Investigations, 2017
- Epithelial‐mesenchymal transition in cancer metastasis through the lymphatic systemMolecular Oncology, 2017
- Regulatory T cells in cancer immunotherapyCell Research, 2016
- Predictors of Survival of Advanced Renal Cell Carcinoma: Long-Term Results From Southwest Oncology Group Trial S8949Journal of Urology, 2009